[go: up one dir, main page]

DK3710576T3 - Til-ekspansion fra finnålsaspirater og små biopsier - Google Patents

Til-ekspansion fra finnålsaspirater og små biopsier Download PDF

Info

Publication number
DK3710576T3
DK3710576T3 DK18827296.7T DK18827296T DK3710576T3 DK 3710576 T3 DK3710576 T3 DK 3710576T3 DK 18827296 T DK18827296 T DK 18827296T DK 3710576 T3 DK3710576 T3 DK 3710576T3
Authority
DK
Denmark
Prior art keywords
til
expansion
needle aspirates
small biopsies
fin
Prior art date
Application number
DK18827296.7T
Other languages
English (en)
Inventor
Michelle Simpson-Abelson
Cecile Chartier-Courtaud
Original Assignee
Iovance Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iovance Biotherapeutics Inc filed Critical Iovance Biotherapeutics Inc
Application granted granted Critical
Publication of DK3710576T3 publication Critical patent/DK3710576T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/852—Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/86—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/54—Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/55—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Hospice & Palliative Care (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
DK18827296.7T 2017-11-17 2018-11-19 Til-ekspansion fra finnålsaspirater og små biopsier DK3710576T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762588044P 2017-11-17 2017-11-17
US201862621515P 2018-01-24 2018-01-24
US201862756038P 2018-11-05 2018-11-05
PCT/US2018/061865 WO2019100023A1 (en) 2017-11-17 2018-11-19 Til expansion from fine needle aspirates and small biopsies

Publications (1)

Publication Number Publication Date
DK3710576T3 true DK3710576T3 (da) 2025-01-02

Family

ID=64901650

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18827296.7T DK3710576T3 (da) 2017-11-17 2018-11-19 Til-ekspansion fra finnålsaspirater og små biopsier

Country Status (18)

Country Link
US (4) US20200277573A1 (da)
EP (2) EP4501408A3 (da)
JP (1) JP7557367B2 (da)
KR (1) KR20200100060A (da)
CN (1) CN111601883B (da)
AU (2) AU2018368786B2 (da)
BR (1) BR112020009663A2 (da)
CA (1) CA3082484A1 (da)
CR (1) CR20200251A (da)
DK (1) DK3710576T3 (da)
ES (1) ES3013486T3 (da)
IL (1) IL274584B2 (da)
MX (1) MX2020004967A (da)
PH (1) PH12020550642A1 (da)
PL (1) PL3710576T4 (da)
SG (1) SG11202004457XA (da)
TW (2) TWI833719B (da)
WO (1) WO2019100023A1 (da)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201522097D0 (en) 2015-12-15 2016-01-27 Cellular Therapeutics Ltd Cells
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
CN110520436A (zh) 2017-03-15 2019-11-29 潘迪恩治疗公司 靶向免疫耐受性
EP3630163A4 (en) 2017-05-24 2021-06-09 Pandion Operations, Inc. Targeted immunotolerance
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US11713446B2 (en) * 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
JP7558563B2 (ja) 2018-03-15 2024-10-01 ケーエスキュー セラピューティクス， インコーポレイテッド 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法
US20220249559A1 (en) * 2019-05-13 2022-08-11 Iovance Biotherapeutics, Inc. Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
MX2021014178A (es) 2019-05-20 2022-01-04 Pandion Operations Inc Inmunotolerancia dirigida a la molecula de adhesion celular de adresina vascular de mucosas (madcam).
US20210285054A1 (en) * 2019-05-28 2021-09-16 Xiling Shen Precision drug screening for personalized cancer therapy
GB201911066D0 (en) 2019-08-02 2019-09-18 Achilles Therapeutics Ltd T cell therapy
US20220389381A1 (en) * 2019-10-25 2022-12-08 Iovance Biotherapeutics, Inc. Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
BR112022011795A2 (pt) 2019-12-20 2022-08-30 Instil Bio Uk Ltd Métodos para preparar e isolar uma população terapêutica de linfócitos e para tratar câncer em um indivíduo, população terapêutica de linfócitos, bolsa criopreservada, recipiente flexível, e, sistema para extração de linfócitos
CN115209925A (zh) * 2020-01-10 2022-10-18 融合制药公司 持续性免疫疗法
EP4107187A4 (en) 2020-02-21 2024-07-03 Pandion Operations, Inc. TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR
US20230108584A1 (en) * 2020-02-28 2023-04-06 KSQ Therapeutics, Inc, Methods for activation and expansion of tumor infiltrating lymphocytes
IL297751A (en) 2020-04-28 2022-12-01 Lyell Immunopharma Inc Methods for culturing cells
WO2021219990A1 (en) 2020-04-28 2021-11-04 Achilles Therapeutics Uk Limited T cell therapy
EP4146794A1 (en) * 2020-05-04 2023-03-15 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
CA3177413A1 (en) * 2020-05-04 2021-11-11 Michelle SIMPSON-ABELSON Selection of improved tumor reactive t-cells
GB202006989D0 (en) * 2020-05-12 2020-06-24 Gammadelta Therapeutics Ltd Methods for isolating gamma delta t cells
US10963804B1 (en) * 2020-07-01 2021-03-30 Sas Institute Inc. Analytic system with extrapolation control in interactive graphical prediction evaluation
CA3172316A1 (en) 2020-11-23 2022-05-27 Lyell Immunopharma, Inc. Methods for culturing immune cells
CA3213163A1 (en) 2021-03-25 2022-09-29 Iovance Biotherapeutics, Inc. Methods and compositions for t-cell coculture potency assays and use with cell therapy products
WO2022214835A1 (en) 2021-04-09 2022-10-13 Achilles Therapeutics Uk Limited Batch release assay for pharmaceutical products relating to t cell therapies
GB202109886D0 (en) 2021-07-08 2021-08-25 Achilles Therapeutics Uk Ltd Assay
AU2022263418A1 (en) * 2021-04-19 2023-10-26 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
CN116406426A (zh) * 2021-04-29 2023-07-07 苏州沙砾生物科技有限公司 一种修饰的肿瘤浸润淋巴细胞及其用途
IL312027A (en) 2021-10-28 2024-06-01 Lyell Immunopharma Inc Methods for culturing immune cells
CA3237410A1 (en) * 2021-11-10 2023-05-19 Friedrich Graf Finck VON FINCKENSTEIN Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
WO2023125772A1 (zh) * 2021-12-30 2023-07-06 苏州沙砾生物科技有限公司 一种修饰的肿瘤浸润淋巴细胞及其用途
WO2023138598A1 (zh) * 2022-01-19 2023-07-27 苏州沙砾生物科技有限公司 肿瘤浸润淋巴细胞在疾病治疗中的用途
JP2025503987A (ja) * 2022-01-28 2025-02-06 アイオバンス バイオセラピューティクス，インコーポレイテッド ペイロードを発現するように操作された腫瘍浸潤リンパ球
WO2025006811A1 (en) 2023-06-27 2025-01-02 Lyell Immunopharma, Inc. Methods for culturing immune cells
AU2024292473A1 (en) 2023-07-19 2026-01-29 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with trop-2 targeting adc
WO2026006604A1 (en) 2024-06-26 2026-01-02 Lyell Immunopharma, Inc. Feeder cell replacement

Family Cites Families (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
WO1988000970A2 (en) * 1986-08-08 1988-02-11 Regents Of The University Of Minnesota Method of culturing leukocytes
US5128257A (en) 1987-08-31 1992-07-07 Baer Bradford W Electroporation apparatus and process
DE68925030T2 (de) 1988-01-21 1996-07-25 Massachusetts Inst Technology Molekültransport durch gewebe mit der verwendung von elektroporation.
US6303121B1 (en) 1992-07-30 2001-10-16 Advanced Research And Technology Method of using human receptor protein 4-1BB
US6362325B1 (en) 1988-11-07 2002-03-26 Advanced Research And Technology Institute, Inc. Murine 4-1BB gene
US4902502A (en) 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5089261A (en) 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
ZA902710B (en) 1989-05-22 1991-12-24 Univ Georgia Res Found Enzyme luminescence assay
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
AU7979491A (en) 1990-05-03 1991-11-27 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
CA2019758C (en) 1990-06-25 2001-09-04 Kevin L. Firth Improved electroporation device and method
US5137817A (en) 1990-10-05 1992-08-11 Amoco Corporation Apparatus and method for electroporation
US5173158A (en) 1991-07-22 1992-12-22 Schmukler Robert E Apparatus and methods for electroporation and electrofusion
US5304120A (en) 1992-07-01 1994-04-19 Btx Inc. Electroporation method and apparatus for insertion of drugs and genes into endothelial cells
US5273525A (en) 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
US5318514A (en) 1992-08-17 1994-06-07 Btx, Inc. Applicator for the electroporation of drugs and genes into surface cells
ES2198414T3 (es) 1992-10-23 2004-02-01 Immunex Corporation Procedimientos para preparar proteinas oligomericas solubles.
GB9317380D0 (en) 1993-08-20 1993-10-06 Therexsys Ltd Transfection process
US5821332A (en) 1993-11-03 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor on the surface of activated CD4+ T-cells: ACT-4
US6989434B1 (en) 1994-02-11 2006-01-24 Invitrogen Corporation Reagents for intracellular delivery of macromolecules
US5691188A (en) 1994-02-14 1997-11-25 American Cyanamid Company Transformed yeast cells expressing heterologous G-protein coupled receptor
EP0769063A1 (en) 1994-06-27 1997-04-23 The Johns Hopkins University Targeted gene delivery system
US5908635A (en) 1994-08-05 1999-06-01 The United States Of America As Represented By The Department Of Health And Human Services Method for the liposomal delivery of nucleic acids
US5827642A (en) * 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US5484720A (en) 1994-09-08 1996-01-16 Genentech, Inc. Methods for calcium phosphate transfection
US5830430A (en) 1995-02-21 1998-11-03 Imarx Pharmaceutical Corp. Cationic lipids and the use thereof
ES2185770T3 (es) 1995-04-08 2003-05-01 Lg Chemical Ltd Anticuerpo monoclonal especifico para 4-1bb humano y linea celular que lo produce.
US5981501A (en) 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
US6010613A (en) 1995-12-08 2000-01-04 Cyto Pulse Sciences, Inc. Method of treating materials with pulsed electrical fields
US5849902A (en) 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
WO1998016249A1 (en) 1996-10-11 1998-04-23 Bristol-Myers Squibb Company Methods and compositions for immunomodulation
US6489458B2 (en) 1997-03-11 2002-12-03 Regents Of The University Of Minnesota DNA-based transposon system for the introduction of nucleic acid into DNA of a cell
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
US6475994B2 (en) 1998-01-07 2002-11-05 Donald A. Tomalia Method and articles for transfection of genetic material
US6312700B1 (en) 1998-02-24 2001-11-06 Andrew D. Weinberg Method for enhancing an antigen specific immune response with OX-40L
ATE466952T1 (de) 1998-03-02 2010-05-15 Massachusetts Inst Technology Poly-zinkfinger-proteine mit verbesserten linkern
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US7013219B2 (en) 1999-01-12 2006-03-14 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6794136B1 (en) 2000-11-20 2004-09-21 Sangamo Biosciences, Inc. Iterative optimization in the design of binding proteins
US20030104526A1 (en) 1999-03-24 2003-06-05 Qiang Liu Position dependent recognition of GNN nucleotide triplets by zinc fingers
US7030215B2 (en) 1999-03-24 2006-04-18 Sangamo Biosciences, Inc. Position dependent recognition of GNN nucleotide triplets by zinc fingers
US6821725B1 (en) * 2000-03-07 2004-11-23 Albert Einstein College Of Medicine Of Yeshiva University Methods for the diagnosis and treatment of breast cancer
CA2300551C (en) * 2000-03-08 2002-06-25 Browne & Co. Ltd. Whisk with wire loops covered with silicon tubing
US7189705B2 (en) 2000-04-20 2007-03-13 The University Of British Columbia Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers
US6627442B1 (en) 2000-08-31 2003-09-30 Virxsys Corporation Methods for stable transduction of cells with hiv-derived viral vectors
AU2000202A (en) 2000-10-31 2002-05-15 Pr Pharmaceuticals Inc Methods and compositions for enhanced delivery of bioactive molecules
ES2295639T3 (es) 2002-06-13 2008-04-16 Crucell Holland B.V. Agonistas del receptor ox40=(=cd134) y uso terapeutico descripcion.
PL375144A1 (en) 2002-07-30 2005-11-28 Bristol-Myers Squibb Company Humanized antibodies against human 4-1bb
JP4399710B2 (ja) 2003-08-13 2010-01-20 株式会社リンフォテック 閉鎖系細胞培養用容器及び該容器を用いた細胞の増殖培養方法、ならびに細胞増殖培養用キット
WO2005035728A2 (en) 2003-10-08 2005-04-21 Wilson Wolf Manufacturing Corporation Cell culture methods and devices utilizing gas permeable materials
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
CN101072578A (zh) 2004-10-29 2007-11-14 南加州大学 用共刺激分子的联合癌症免疫疗法
DK1877090T3 (da) 2005-05-06 2014-04-14 Providence Health System Trimert ox40-immunoglobulin-fusionsprotein og fremgangsmåder til anvendelse heraf
MX2007013978A (es) 2005-05-09 2008-02-22 Ono Pharmaceutical Co Anticuerpos monoclonales humanos a muerte programada 1 (pd-1) y metodos para tratamiento de cancer utilizando anticuerpos anti-pd-1 solos o en combinacion con otros inmunoterapeuticos.
CN105330741B (zh) 2005-07-01 2023-01-31 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
WO2007020880A1 (ja) 2005-08-17 2007-02-22 Takara Bio Inc. リンパ球の製造方法
TWI466269B (zh) 2006-07-14 2014-12-21 Semiconductor Energy Lab 非揮發性記憶體
EP1894940A1 (en) 2006-08-28 2008-03-05 Apogenix GmbH TNF superfamily fusion proteins
AU2008219666A1 (en) 2007-02-27 2008-09-04 Genentech, Inc. Antagonist OX40 antibodies and their use in the treatment of inflammatory and autoimmune diseases
EP3321277B1 (en) 2007-07-10 2019-09-18 Apogenix AG Tnf superfamily collectin fusion proteins
CA2702028A1 (en) 2007-10-02 2009-04-09 Rxi Pharmaceuticals Corp. Tripartite rnai constructs
DK2242771T3 (da) 2007-12-14 2013-08-26 Pfizer Bindingsmolekyler til den humane ox40-receptor
JP5697993B2 (ja) 2008-02-11 2015-04-08 アールエックスアイ ファーマシューティカルズ コーポレーション 修飾ＲＮＡｉポリヌクレオチドおよびその使用
DK2250498T3 (da) * 2008-02-25 2013-02-04 Nestec Sa Lægemiddelvalg til brystcancerterapi under anvendelse af antistof-baserede arrays
ES2524553T3 (es) 2008-06-17 2014-12-10 Apogenix Gmbh Receptores multiméricos de TNF
HUE025236T2 (en) 2008-07-21 2016-03-29 Apogenix Gmbh TNFSF single chain molecules
JP2012502991A (ja) 2008-09-22 2012-02-02 アールエックスアイ ファーマシューティカルズ コーポレーション 皮膚適用におけるｒｎａ干渉
WO2010042433A1 (en) 2008-10-06 2010-04-15 Bristol-Myers Squibb Company Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases
EP2382236B1 (en) 2009-01-09 2016-08-17 Apogenix AG Fusion proteins forming trimers
US8383099B2 (en) * 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
US20130115617A1 (en) 2009-12-08 2013-05-09 John R. Wilson Methods of cell culture for adoptive cell therapy
US8956860B2 (en) 2009-12-08 2015-02-17 Juan F. Vera Methods of cell culture for adoptive cell therapy
CN102762719A (zh) 2009-12-08 2012-10-31 威尔森沃尔夫制造公司 用于过继细胞疗法的细胞培养的改进方法
EP3560503B1 (en) 2010-03-24 2021-11-17 Phio Pharmaceuticals Corp. Rna interference in dermal and fibrotic indications
CN103200945B (zh) 2010-03-24 2016-07-06 雷克西制药公司 眼部症候中的rna干扰
US9080171B2 (en) 2010-03-24 2015-07-14 RXi Parmaceuticals Corporation Reduced size self-delivering RNAi compounds
EP3156062A1 (en) 2010-05-17 2017-04-19 Sangamo BioSciences, Inc. Novel dna-binding proteins and uses thereof
JP2013534417A (ja) 2010-06-14 2013-09-05 アイオワ ステート ユニバーシティ リサーチ ファウンデーション，インコーポレーティッド Ｔａｌエフェクターとｆｏｋｉの融合タンパク質のヌクレアーゼ活性
AP2013006771A0 (en) 2010-08-23 2013-03-31 Boards Of Regents The University Of Texas System Anti-OX40 antibodies and methods of using the same
WO2013028231A1 (en) 2011-08-23 2013-02-28 Board Of Regents, The University Of Texas System Anti-ox40 antibodies and methods of using the same
SI2614082T1 (sl) 2010-09-09 2018-12-31 Pfizer Inc. Molekule, ki vežejo 4-1BB
US8962804B2 (en) 2010-10-08 2015-02-24 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
DK2637694T3 (da) 2010-11-12 2021-06-07 Nektar Therapeutics KONJUGATER AF EN Il-2-ENHED OG EN POLYMER
WO2012129201A1 (en) 2011-03-22 2012-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
EP2694089B1 (en) 2011-04-05 2024-06-05 Cellectis New tale-protein scaffolds and uses thereof
US20140234320A1 (en) 2011-06-20 2014-08-21 La Jolla Institute For Allergy And Immunology Modulators of 4-1bb and immune responses
BR112014006176A8 (pt) 2011-09-16 2017-09-12 Univ Pennsylvania Rna transcrito in vitro ou rna sintético, composição, método para gerar uma população de células t geneticamente modificadas por rna, e, uso de uma célula t geneticamente modificada
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
CN103987836B (zh) 2011-10-17 2018-04-10 麻省理工学院 细胞内传递
JP6142142B2 (ja) 2012-04-10 2017-06-07 株式会社リンフォテック メモリーｔ細胞を主成分とするリンパ球細胞群の製造方法
IL307674A (en) 2012-05-18 2023-12-01 Wilson Wolf Mfg Corporation Improved methods of cell culture for adoptive cell therapy
PL2855667T3 (pl) 2012-05-25 2024-03-25 Cellectis Sposoby uzyskiwania metodami inżynierii allogenicznych i opornych na immunosupresję limfocytów t do immunoterapii
EP2855671B1 (en) 2012-06-05 2019-02-20 Cellectis Transcription activator-like effector (tale) fusion protein
SG11201407819UA (en) 2012-06-11 2014-12-30 Wolf Wilson Mfg Corp Improved methods of cell culture for adoptive cell therapy
US20140310830A1 (en) 2012-12-12 2014-10-16 Feng Zhang CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
EP3825401A1 (en) 2012-12-12 2021-05-26 The Broad Institute, Inc. Crispr-cas component systems, methods and compositions for sequence manipulation
US8993233B2 (en) 2012-12-12 2015-03-31 The Broad Institute Inc. Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
CN113528577B (zh) 2012-12-12 2024-12-03 布罗德研究所有限公司 用于序列操纵的系统、方法和优化的指导组合物的工程化
IL300461A (en) 2012-12-12 2023-04-01 Harvard College Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
CN105163744A (zh) 2013-03-01 2015-12-16 美国卫生和人力服务部 从肿瘤中产生肿瘤反应性t细胞的富集群的方法
DK2976361T3 (da) 2013-03-18 2018-10-01 Biocerox Prod Bv Humaniserede anti-cd134- (0x40) antistoffer og anvendelser deraf
CN103396991A (zh) * 2013-05-02 2013-11-20 陈晚华 一种快速高效扩增肿瘤浸润性淋巴细胞的方法
US11311575B2 (en) 2013-05-13 2022-04-26 Cellectis Methods for engineering highly active T cell for immunotherapy
AU2014302589B2 (en) 2013-06-24 2020-05-14 Wilson Wolf Manufacturing, LLC Closed system device and methods for gas permeable cell culture process
WO2015084897A2 (en) 2013-12-02 2015-06-11 Mirimmune, Llc Immunotherapy of cancer
JP2017501167A (ja) 2013-12-17 2017-01-12 ジェネンテック， インコーポレイテッド Ｏｘ４０結合アゴニスト及びｐｄ−１軸結合アンタゴニストを含む併用療法
EP3102604B1 (en) 2014-02-04 2020-01-15 Pfizer Inc Combination of a pd-1 antagonist and a 4-1bb agonist for treating cancer
WO2015157636A1 (en) 2014-04-10 2015-10-15 H. Lee Moffitt Cancer Center And Research Institute, Inc. Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy
CN106574244B (zh) 2014-06-11 2022-01-07 保利比奥斯博特有限责任公司 用细胞因子组合物扩增淋巴细胞用于主动细胞免疫治疗
JP6686008B2 (ja) * 2014-10-02 2020-04-22 アメリカ合衆国 がん特異的突然変異に対し抗原特異性を有するｔ細胞受容体を単離する方法
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
CN107922911A (zh) 2015-07-09 2018-04-17 麻省理工学院 将物质递送至无核细胞
IL295616A (en) * 2015-07-31 2022-10-01 Us Health Adapted cells and treatment methods
US11021707B2 (en) 2015-10-19 2021-06-01 Phio Pharmaceuticals Corp. Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA
TWI808934B (zh) * 2015-12-31 2023-07-21 美商伯克利之光生命科技公司 經工程化以表現促發炎多肽之腫瘤浸潤細胞
CN116218916A (zh) 2016-01-12 2023-06-06 Sqz生物技术公司 复合物的细胞内递送
EP3430130B1 (en) * 2016-03-14 2023-01-04 Wisconsin Alumni Research Foundation Methods of t cell expansion and activation
KR20240150531A (ko) * 2016-10-26 2024-10-15 이오반스 바이오테라퓨틱스, 인크. 냉동보존된 종양 침윤 림프구의 재자극
JOP20190224A1 (ar) 2017-03-29 2019-09-26 Iovance Biotherapeutics Inc عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي

Also Published As

Publication number Publication date
EP4501408A3 (en) 2025-04-09
AU2018368786B2 (en) 2025-05-22
JP7557367B2 (ja) 2024-09-27
US20240398946A1 (en) 2024-12-05
ES3013486T3 (en) 2025-04-14
US20210309968A1 (en) 2021-10-07
BR112020009663A2 (pt) 2020-11-10
EP3710576B1 (en) 2024-10-02
CA3082484A1 (en) 2019-05-23
CN111601883B (zh) 2024-06-21
SG11202004457XA (en) 2020-06-29
EP3710576A1 (en) 2020-09-23
US20200277573A1 (en) 2020-09-03
US20250188413A1 (en) 2025-06-12
PL3710576T3 (pl) 2025-02-24
PL3710576T4 (pl) 2025-04-28
AU2018368786A1 (en) 2020-06-18
WO2019100023A1 (en) 2019-05-23
EP4501408A2 (en) 2025-02-05
TWI833719B (zh) 2024-03-01
IL274584A (en) 2020-06-30
TW202446951A (zh) 2024-12-01
IL274584B2 (en) 2025-01-01
MX2020004967A (es) 2020-08-27
PH12020550642A1 (en) 2021-03-22
CR20200251A (es) 2020-07-17
KR20200100060A (ko) 2020-08-25
AU2025220776A1 (en) 2025-09-11
CN111601883A (zh) 2020-08-28
IL274584B1 (en) 2024-09-01
JP2021503281A (ja) 2021-02-12
TW201932594A (zh) 2019-08-16

Similar Documents

Publication Publication Date Title
DK3710576T3 (da) Til-ekspansion fra finnålsaspirater og små biopsier
DK3806744T3 (da) Øjeblikkelig undersøgelse
EP3749218C0 (en) BIOPSY DEVICE
SI3606954T1 (sl) Protitelesa proti LAG3
DK3849414T3 (da) Åndedrætsprøvetager
DK3288467T3 (da) Biopsiindretning
DK3443009T3 (da) Anti-tim-3-antistoffer og sammensætninger
EP3775831C0 (en) SAMPLING DEVICE
EP4234111C0 (en) CLASSIFICATION APPARATUS
DK3497427T3 (da) Bærbar luftprøvetager
EP3998801C0 (en) DATA TRANSFER PROCESS
EP3544518C0 (en) SINGLE-INSERT MULTI-SAMPLE BIOPSY DEVICE
EP3565457C0 (en) DETECTION DEVICE
EP3713500C0 (en) BALLOON ANCHORED BIOPSY DEVICE
DK3611514T3 (da) Prøveanalyseindretning
EP3865634C0 (en) INSERTION DEVICE
DK3716870T3 (da) Endoskopisk snare
EP3723619C0 (en) IMPEDANCE MEASURING PROBE AND BIOPSY DEVICE
EP3581936A4 (en) AUTOMATIC ANALYSIS DEVICE
EP3751266A4 (en) SAMPLE HOLDER
EP3312614A4 (en) sample analyzer
EP3596440A4 (en) PIPELINE SAMPLER
EP3605220A4 (en) BLOCKING DEVICE
DK3288674T3 (da) Røreorgananordning
EP3669196C0 (en) TEST DEVICE